Mitral Valve

The heart's mitral valve is the site of the most surgical valve repairs and valve replacements. After the resounding success of transcatheter aortic valve replacement (TAVR), which now makes up more than 50% of aortic valve replacements, there is wide expectation transcatheter mitral replacements will follow in the next few year. Currently, the most common transcatheter mitral procedure is transcatheter edge-to-edge (TEER) , using the MitraClip or Pascal clip devices. These devices are also being used for transcatheter tricuspid valve repair (TTVR). Other transcatheter mitral repair systems are in trials for minimally invasive annuloplasty and chordae tendineae repair.

How robotic-assisted mitral valve repair compares to conventional surgery
Costs remain a concern, especially for low-volume centers, but robotic-assisted MV repair is associated with short-term outcomes comparable to more conventional techniques.
LAMPOON before TMVR improves symptoms without complications, long-term data confirm
LVOT obstruction remains a significant complication of TMVR, making the long-term safety and effectiveness of the LAMPOON technique a hot topic in interventional cardiology.
Baseline TR linked to lower quality of life after TAVR, M-TEER—are more interventions the answer?
Patients presenting for TAVR or M-TEER with baseline moderate or severe tricuspid regurgitation were associated with lower post-treatment KCCQ scores and a higher mortality rate. Perhaps treating more of these patients with tricuspid valve repair or replacement could make a difference, researchers noted.
Atrial functional mitral regurgitation: Surgery improves outcomes more than medical therapy alone
"These findings underscore the importance of understanding AFMR and its treatment options," one cardiologist said.
TEER with Abbott’s MitraClip linked to low stroke risk, new study confirms
Treating severe MR with the popular device does not appear to increase a patient's risk of stroke or transient ischemic attack. When patients present with AFib, however, care teams may want to make certain adjustments to optimize outcomes.

TMVR with MitraClip increases life expectancy—at a cost

An economic analysis of COAPT data suggests edge-to-edge TMVR with the MitraClip device is a more affordable long-term treatment option than guideline-directed medical therapy alone for patients with severe secondary MR—but the steep cost of an index TMVR procedure might eclipse that benefit.

October 1, 2019

3-year COAPT results bolster MitraClip’s success

Results from the COAPT study continue to roll in, and it was all positive news for the MitraClip team at the TCT conference in San Francisco this month.

September 30, 2019

COAPT: Patients with HF, mitral regurgitation see better health outcomes with TMVR

A recent analysis of the COAPT trial, published this spring in the Journal of the American College of Cardiology, suggests patients with symptomatic heart failure (HF) and secondary mitral regurgitation (MR) might see better mental and physical outcomes if they’re treated with edge-to-edge transcatheter mitral valve repair (TMVR) in lieu of standard therapy.

May 30, 2019

Edwards’ Pascal TMVR system gains CE mark

The Pascal transcatheter mitral valve repair (TMVR) system has received its CE mark for the treatment of patients with mitral regurgitation, device manufacturer Edwards Lifesciences announced Feb. 19.

February 20, 2019

Transcatheter treatments catching up to surgical mitral valve repair

The use of transcatheter mitral valve repair (TMVR) systems continues to grow rapidly nearly six years after the FDA approved the U.S.'s first such treatment, according to research published in the American Journal of Cardiology. In contrast, rates of surgical mitral valve repair (SMVR) have remained steady.

January 28, 2019

The Cephea transcatheter mitral valve in development has been acquired by Medtronic.

Abbott acquires another TMVR device through purchase of Cephea

Abbott plans to acquire Cephea Valve Technologies, a company developing a transcatheter mitral valve replacement (TMVR) device, the Chicago-area healthcare giant announced Jan. 16.

January 16, 2019

After COAPT: Getting MitraClip Right in the Real World

Will operators be able to replicate COAPT’s restraint and its outcomes?

January 7, 2019

TMVR device nearly wipes out mitral regurgitation

An investigational transcatheter mitral valve replacement (TMVR) device helped reduce mitral regurgitation to zero or trace levels in 98.7 percent of patients, according to 30-day follow-up data from the first 100 people scheduled to be treated with Abbott’s Tendyne system.

May 24, 2018

Mitral Valve

How robotic-assisted mitral valve repair compares to conventional surgery

LAMPOON before TMVR improves symptoms without complications, long-term data confirm

Baseline TR linked to lower quality of life after TAVR, M-TEER—are more interventions the answer?

Atrial functional mitral regurgitation: Surgery improves outcomes more than medical therapy alone

TEER with Abbott’s MitraClip linked to low stroke risk, new study confirms